Is Vitamin C Supplementation in Patients with β-Thalassemia Major Beneficial or Detrimental?

doi:10.1080/03630269.2016.1190373

Paper

Is Vitamin C Supplementation in Patients with β-Thalassemia Major Beneficial or Detrimental?

Published Jul 3, 2016 · Hadi Darvishi Khezri, Amir Emami Zeydi, H. Sharifi

Hemoglobin

13

Citations

0

Influential Citations

Full text

Abstract

Abstract Globally, β-thalassemia major (β-TM) is one of the most common hereditary disorders. Multiple blood transfusions, that are a life-saving therapy in patients with β-TM, is a major source of iron overload. Iron overload can lead to significant morbidity and mortality. Research evidence indicates that oxidative stress induced by iron overload, is one of the major precipitating causes of vitamin C deficiency in β-TM patients. It has previously been shown that patients with β-TM have significantly lower levels of vitamin C as compared to healthy individuals. It is believed that vitamin C can reduce both ferric (Fe3+) and ferrous (Fe2+) ions, and also facilitate the accessibility of iron to chelators through increase of iron release from the reticuloendothelial system. Despite the potential benefits of vitamin C in patients with β-TM, several areas of concern exist that should be addressed by high quality research designs. Some recommendations have been provided through this study.

Study Snapshot

Vitamin C supplementation may be beneficial for patients with -thalassemia major, but further high-quality research is needed to address potential concerns.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Is Vitamin C Supplementation in Patients with β-Thalassemia Major Beneficial or Detrimental?

References

Citations